Fibroblast growth factor-21: a metabolic regulator or something more?
Salgado, João Victor; Salgado, Bernardete Jorge.
Clin Endocrinol (Oxf)
; 81(6): 938-40, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24890012
Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction.
Extrarenal effects of FGF23.
FGF23 from bench to bedside.
Fibroblast Growth Factor 23 Predicts All-Cause Mortality in a Dose-Response Fashion in Pre-Dialysis Patients with Chronic Kidney Disease.
No apparent link between serum Klotho and phosphate in human chronic kidney disease.
Copeptin Associates with Cause-Specific Mortality in Patients with Impaired Renal Function: Results from the LURIC and the 4D Study.
[Correlation of fibroblast growth factor 23 with adverse prognosis of chronic kidney disease andtherapy strategy].
Dynamic Analysis of Kidney Function and Its Correlation with Nutritional Indicators in a Large Sample of Hospitalized Elderly Patients.
Enhanced induction of Cyp24a1 by FGF23 but low serum 24,25-dihydroxyvitamin D in CKD: implications for therapy.
Using the hazard ratio to evaluate allowable total error in predictive measurands.